James Howard-Tripp
Chief Executive Officer bei STAGEZERO LIFE SCIENCES LTD.
Vermögen: 8 147 $ am 31.03.2024
Profil
James R.
Howard-Tripp is currently the Executive Chairman & Chief Executive Officer at StageZero Life Sciences Ltd.
He is also the Chief Executive Officer at Innovative Diagnostic Laboratory LLP, the President & Director at GeneNews (USA), Inc., and a Founding Member of the Canadian Healthcare Licensing Association.
Previously, he served as the President, Chief Executive Officer & Director at Labopharm, Inc. from 2010 to 2011.
He was also the Chief Executive Officer at Paladin Labs Europe Ltd., the President & Chief Executive Officer at Allelix Neuroscience, Inc., and the Senior Vice President-Operations at Allelix Biopharmaceuticals, Inc. Additionally, he held the position of Vice President-Business Development at Wyeth Ayerst Canada, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.04.2023 | 232 759 ( 0,19% ) | 8 147 $ | 31.03.2024 |
Aktive Positionen von James Howard-Tripp
| Unternehmen | Position | Beginn |
|---|---|---|
| STAGEZERO LIFE SCIENCES LTD. | Chief Executive Officer | 10.08.2016 |
| Canadian Healthcare Licensing Association | Corporate Officer/Principal | 20.08.2009 |
Innovative Diagnostic Laboratory LLP
 Innovative Diagnostic Laboratory LLP Medical/Nursing ServicesHealth Services Innovative Diagnostic Laboratory LLP offers risk assessment blood tests to find, understand, and treat cancer for the prevalent cancer types. Its products include colonsentry, earlyCDT-Lung, and prostate health index. The company is headquartered in Richmond, VA. | Chief Executive Officer | - |
GeneNews (USA), Inc.
 GeneNews (USA), Inc. Medical SpecialtiesHealth Technology GeneNews (USA), Inc. operates as a cancer diagnostics company. The firm focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The company was incorporated on August 20, 2013 and is headquartered in Glen Allen, VA. | President | - |
Ehemalige bekannte Positionen von James Howard-Tripp
| Unternehmen | Position | Ende |
|---|---|---|
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Chief Executive Officer | 14.03.2011 |
| Allelix Biopharmaceuticals, Inc. | Chief Operating Officer | - |
| Wyeth Ayerst Canada, Inc. | Corporate Officer/Principal | - |
| Allelix Neuroscience, Inc. | President | - |
| Paladin Labs Europe Ltd. | President | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| STAGEZERO LIFE SCIENCES LTD. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
| Allelix Biopharmaceuticals, Inc. | Health Technology |
| Paladin Labs Europe Ltd. | |
| Canadian Healthcare Licensing Association | |
| Allelix Neuroscience, Inc. | |
| Wyeth Ayerst Canada, Inc. | |
Innovative Diagnostic Laboratory LLP
Innovative Diagnostic Laboratory LLP Medical/Nursing ServicesHealth Services Innovative Diagnostic Laboratory LLP offers risk assessment blood tests to find, understand, and treat cancer for the prevalent cancer types. Its products include colonsentry, earlyCDT-Lung, and prostate health index. The company is headquartered in Richmond, VA. | Health Services |
GeneNews (USA), Inc.
GeneNews (USA), Inc. Medical SpecialtiesHealth Technology GeneNews (USA), Inc. operates as a cancer diagnostics company. The firm focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The company was incorporated on August 20, 2013 and is headquartered in Glen Allen, VA. | Health Technology |
